Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MCV-5
- Development stage
- Preclinical
- Lead developer
- AJ Vaccines
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MCV-5 is a pentavalent meningococcal conjugate vaccine being developed by AJ Vaccines in collaboration with Hilleman Laboratories. It is designed to provide protection against five serogroups of *Neisseria meningitidis* (A, C, W, Y, and X), expanding upon the coverage provided by existing quadrivalent vaccines. The vaccine utilizes conjugated capsular antigens to induce antibody-mediated immunity, specifically targeting invasive meningococcal infections such as meningitis and septicemia. The partnership between AJ Vaccines and Hilleman Laboratories (a joint venture between Merck/MSD and the Wellcome Trust) aims to provide an affordable and effective solution for regions with a high burden of meningococcal disease, particularly the African meningitis belt.
- Other names
- Meningococcal Conjugate Vaccine, 5 serogroupsPentavalent Meningococcal Conjugate Vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)MenX CPS (Neisseria meningitidis serogroup X capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on MCV-5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MCV-5.